Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Daré Bioscience, Inc. develops and commercializes women’s health therapies across contraception, fertility, vaginal health, and sexual health. Its updates center on XACIATO, DARE to PLAY™ Sildenafil Cream, and investigational programs such as DARE-HPV and DARE-PTB1, an intravaginal ring program for prevention of preterm birth.
Recurring news themes include financial results, company updates, product availability through prescription and 503B channels, FDA and IND-related development milestones, clinical-program disclosures, and non-dilutive funding from government sources. Coverage also reflects Daré’s public reporting on product candidates, trials, financing, and business development.
Daré Bioscience (NASDAQ: DARE) has initiated a Phase 1 clinical trial for DARE-HRT1, aimed at delivering bio-identical hormones over 28 days to treat menopausal symptoms and prevent bone loss. This IVR product could be the first FDA-approved option following NAMS guidelines. The study will assess pharmacokinetics and safety in post-menopausal women. Conducted in Australia, the trial also allows for potential cash credits from the R&D tax incentive. The technology promises to enhance convenience and effectiveness in hormone therapy.
Daré Bioscience (NASDAQ: DARE) has published a literature review in Biology of Reproduction, highlighting positive results from a postcoital test (PCT) study of their hormone-free contraceptive, Ovaprene. The review concludes that PCT is a strong predictor of contraceptive effectiveness. Furthermore, if Ovaprene's clinical trial success aligns with previous studies, it may achieve contraceptive effectiveness rates of 86-91% comparable to traditional methods. Daré has an exclusive licensing agreement with Bayer for U.S. commercialization, which could yield up to $310 million in milestone payments and royalties.
Daré Bioscience (NASDAQ: DARE) announced it received an additional $1.5 million grant from the Bill & Melinda Gates Foundation, enhancing its development of the DARE-LARC1 contraceptive program. This funding is part of a previous $18 million commitment from the foundation, with an expectation of another $1 million by year-end. DARE-LARC1 aims to deliver precise drug doses from an implant, allowing user-controlled release. The company is focused on advancing innovative women's health products, including several clinical candidates.
Daré Bioscience (NASDAQ: DARE) announced its participation in the BIO Digital International Convention from June 8-12, 2020. CEO Sabrina Martucci Johnson will join a panel titled Redefining BioPharma in a Female-Forward World and deliver a company presentation. Both sessions will be available on-demand for registered attendees. Daré focuses on innovative women's health solutions including contraceptives and treatments for sexual health and bacterial vaginosis. The company aims to enhance treatment options and improve health outcomes for women.
Daré Bioscience (NASDAQ: DARE) has partnered with Health Decisions to enhance its clinical development for women's health products. This exclusive agreement assigns Health Decisions to provide CRO services in the U.S. for three years, focusing on Daré's reproductive health assets, including its pivotal Ovaprene® study and the DARE-BV1 Phase 3 study in bacterial vaginosis. The collaboration aims to leverage Health Decisions’ expertise and reduce clinical development costs. The partnership could expedite the advancement of innovative treatments in contraception, fertility, and gynecological disorders.
Daré Bioscience (NASDAQ: DARE) announced a conference call on May 14, 2020, at 4:30 p.m. ET to discuss Q1 2020 financial results and provide a company update. Investors can join the call by dialing (844) 831-3031 or through a live webcast available on their website. The company focuses on women's health innovations, with products in development including Ovaprene, Sildenafil Cream, DARE-BV1, and DARE-HRT1. The call will be accessible for replay until May 21, 2020.
Summary not available.